Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-Week Safety, Efficacy, and Pharmacokinetics of Teduglutide in Japanese Adults with Short Bowel Syndrome
jRCT2080224116Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS) and intestinal failure (IF), sponsored by Takeda. Primary endpoints: Change in parenteral support volume and Safety and tolerability of teduglutide. Started Oct 2018; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on jRCT2080224116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224116.